Veterinary diagnostics market projected to reach $19.63 billion by 2032, report says

The global veterinary diagnostics market is expected to grow from $9.72 billion in 2025 to $19.63 billion by 2032, according to a new report from Maximize Market Research. The firm attributes the projected growth to rising pet ownership, greater zoonotic disease surveillance, and expanding livestock production.
Two professional veterinarians take a blood test from a Maine Coon cat at a veterinary clinic. A laboratory technician holds a test tube with tomcat's blood in his hands. Work of the veterinary lab
  • Maximize Market Research projects the veterinary diagnostics market will grow at a 10.56% CAGR from 2026 to 2032.
  • The market is forecast to increase from $9.72 billion in 2025 to $19.63 billion by 2032.
  • Growth drivers cited in the report include preventive animal healthcare, zoonotic disease monitoring, and increased livestock production.
  • The report points to continued expansion in point-of-care testing, molecular diagnostics, immunoassays, and AI-enabled diagnostic platforms.
  • North America currently leads the market, while Asia-Pacific and Latin America are identified as key growth regions.
  • Cost, rural infrastructure gaps, and varying regulatory frameworks remain barriers to wider adoption.

The global veterinary diagnostics market is on track for sustained growth through 2032, according to a new analysis from Maximize Market Research, which estimates the sector will nearly double in value over the forecast period.

The report projects the market will rise from $9.72 billion in 2025 to $19.63 billion by 2032, representing a compound annual growth rate of 10.56%.

Growth tied to preventive care and disease surveillance

According to the report, demand for veterinary diagnostics is being supported by several long-term trends, including increased pet ownership, broader awareness of zoonotic disease threats, and expansion in livestock production.

The report highlights growing use of diagnostics in preventive animal healthcare, particularly for early disease detection and herd health monitoring. Technologies named in the analysis include ELISA-based immunoassays, PCR-based molecular diagnostics, automated analyzers, and point-of-care testing platforms.

AI and rapid testing remain areas of focus

Maximize Market Research also points to the adoption of AI-enabled diagnostic systems and cloud-based platforms as an emerging factor in market development. The report says veterinary professionals and livestock managers are increasingly using rapid tests and multiplex immunoassays to improve turnaround times and support earlier intervention.

It also cites telemedicine and mobile diagnostic tools as part of a broader shift toward expanding access to veterinary care in remote and underserved regions.

Regional growth trends vary

North America leads the market, according to the report, supported by strong veterinary laboratory infrastructure, widespread pet ownership, and investment in research and development.

Europe remains a significant market as well, driven by regulatory standards, disease surveillance efforts, and adoption of advanced diagnostics in both companion animal and livestock settings.

Meanwhile, Asia-Pacific and Latin America are identified as emerging growth regions, with demand linked to livestock expansion, zoonotic disease awareness, and increased investment in farm health monitoring and laboratory capacity.

Challenges continue to shape adoption

The report notes that high costs associated with advanced diagnostic technologies may limit uptake in smaller practices and developing markets. It also identifies infrastructure limitations in rural areas and differing regulatory pathways across countries as ongoing obstacles for broader commercialization and use.

Market segments and competitive activity

Maximize Market Research segments the veterinary diagnostics market by product, species, testing type, disease type, and end use. Laboratories are identified as the leading end-use segment, with the report stating they account for nearly half of market share due to their role in molecular testing, immunoassays, and high-throughput diagnostics.

The report also references recent competitive activity among major companies in the space, including IDEXX Laboratories, Zoetis, Heska, Thermo Fisher Scientific, Antech Diagnostics, QIAGEN, and bioMerieux.

Among developments cited, the report mentions IDEXX’s expansion of its oncology diagnostics portfolio in February 2026, Zoetis’ launch of an AI-powered hematology analyzer in January 2025, and Mars Petcare’s acquisition of Heska in 2023.

Information sourced from the company’s press release.

Never Miss an Animal Health Story

Sign up for free to receive the latest veterinary news, product announcements, and industry developments.